omalizumab
omalizumab: 9 clinical trials tracked.
omalizumab evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
What is verified about omalizumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 4 study sponsors
Clinical Trials (9)
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD (COPD-OMA)
Primary endpoint: Rate of COPD exacerbations
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial of Exl-111 in Healthy Participants
Primary endpoint: Incidence and severity of treatment-emergent adverse events and serious adverse events for Part A and Part B
A Multicenter, Randomized, Double-Blind, Active Drug and Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in the Treatment of Patients With Moderate to Severe Persistent Allergic Asthma.
Primary endpoint: Mean number of asthma exacerbations per subject
Multi-center,Randomized,Double-blind Phase II Study to Evaluate the Efficacy and Safety of LP-003 in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Primary endpoint: The proportion of participants achieving complete absence of wheals and itching (UAS7 = 0) at week 12
A Global, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib 25 mg b.i.d. in Comparison to Placebo With Omalizumab 300 mg Every 4 Weeks as Active Control Over 52 Weeks in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines and an Open-label 52-week Optional Extension to Assess Long-term Efficacy, Safety and Tolerability of Remibrutinib 25 mg b.i.d.
Primary endpoint: Absolute change from baseline in Weekly Urticaria Activity Score (UAS7)
Omalizumab Before Onset of Exacerbations
Primary endpoint: Nasal interferon-α (IFN-α)
A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients
Primary endpoint: Change From Baseline to Week 24 in Nasal Polyp Score
Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies
Primary endpoint: Proportions of patients with Adverse events (AEs), Serious AEs, AEs leading to discontinuation of Xolair treatment, Adverse drug reactions (ADRs), Serious ADRs, ADRs leading to discontinuation of Xolair treatment
Phase 2 Randomized Controlled Trial Using Biologics to Improve Multi OIT Outcomes
Primary endpoint: The Success Rates of Passing a Peanut Double-Blind Placebo Controlled Food Challenge (DBPCFC)